BTIG Rates Sensei Biotherapeutics (SNSE) buy, $55 Price Target

BTIG's analyst Jeet Mukherjee reaffirms a buy rating on Sensei Biotherapeutics and sets a price target of $55, a 323.08% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:14 PM EDT · Updated Jun 14, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Sensei Biotherapeutics Inc ($SNSE) "buy" with a $55 price target on June 11, 2026.

Key Points

BTIG analyst Jeet Mukherjee reiterated a buy rating on Sensei Biotherapeutics Inc. (SNSE), with a target price set at $55. The stock is currently trading at $13.0, which suggests significant upside potential based on Mukherjee's target.
Sensei Biotherapeutics is involved in developing innovative cancer therapies, including PIKTOR and Solnerstotug, which are in clinical stages targeting various cancers. The company's market cap stands at approximately $18.6 million.
Currently, the consensus from analysts indicates a strong buy recommendation for SNSE, with a mean price target of $51.67 based on three analyst opinions.

Get $SNSE trade alerts by text

We text you when insiders, Congress or big funds trade $SNSE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Sensei Biotherapeutics Inc alert may contain errors. Disclosures

BTIG Reiterates Buy Rating on SNSE

BTIG analyst Jeet Mukherjee has reiterated a buy rating on Sensei Biotherapeutics Inc. (SNSE), setting a price target of $55. The stock trades at $13.0, suggesting there could be a significant upside if the target is reached.

What Changed in BTIG's View?

Mukherjee's latest rating indicates confidence in Sensei's potential. With the target price of $55, this move suggests BTIG expects substantial growth in the company's valuation, driven by its ongoing development in cancer therapeutics.

What SNSE Does

Sensei Biotherapeutics, based in Rockville, Maryland, focuses on discovering and developing treatments for cancer patients. Their key products include PIKTOR and Solnerstotug, both designed to tackle various forms of cancer through innovative mechanisms.

How SNSE Stock Has Traded

The stock price of SNSE, currently at $13.0, is significantly below BTIG's target price of $55. This discrepancy indicates a potential for considerable growth, especially as the company continues to advance its clinical-stage therapies in the competitive biotechnology sector.

Recent Earnings

Sensei Biotherapeutics has not reported earnings in this filing, but the company continues to develop promising treatments targeted at cancer. Investors will be keenly interested in future updates regarding clinical trials and revenue potential.

Analysts Set New Price Targets

Beyond BTIG, the consensus among analysts suggests a strong buy recommendation for SNSE, with a mean price target averaging around $51.67 based on three opinions. This consensus reflects a positive outlook on the company's growth prospects in the biotechnology field.

What to Watch at SNSE

As Sensei Biotherapeutics advances in its drug development, investors should keep an eye on upcoming clinical trial results and any further analyst ratings. The buy rating and price target from BTIG highlight continued interest in the stock, which may provide opportunities for growth as the company evolves. Remember, the current analyst opinions were based on the latest data, and the 13F filings reflect positions that may not represent current holdings.